Transgene, a biotech company designing and developing virus-based immunotherapies for the treatment of solid tumors, announces that the independent Data Monitoring Committee (IDMC) of the PHOCUS study of Pexa-Vec in Liver Cancer has completed a planned interim futility analysis.
Pfizer’s rivipansel has failed to meet its primary and key secondary efficacy endpoints in phase 3 study of sickle cell disease (SCD).
Novartis said that its CDK4/6 inhibitor Kisqali (ribociclib) in combination with fulvestrant could deliver a statistically significant improvement in overall survival in a phase 3 trial, called MONALEESA-3.
SpringWorks Therapeutics has secured orphan drug designation from the European Commission (EC) for its mirdametinib to treat neurofibromatosis type 1 (NF1).
Eli Lilly and Company (Lilly) said that Verzenio (abemaciclib) in combination with fulvestrant significantly extended life in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer in a phase 3 trial.
Merck said that Keytruda in combination with chemotherapy has met one of the two primary endpoints of a phase 3 trial in triple-negative breast cancer (TNBC).
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, announced that data from the phase III TANGO study showed that the 2-drug regimen (2DR) of Dovato (dolutegravir/lamivudine) has similar efficacy to a tenofovir alafenamide fumarate (TAF)-containing regimen of at least three drugs in virally supressed and stable adults with HIV-1.
Bristol-Myers Squibb (BMS) has announced the mixed results from the phase 3 CheckMate -227 trial of the lung cancer drug Opdivo (nivolumab).
ViiV Healthcare said that a phase 3 trial of fostemsavir in heavily treatment-experienced adults with HIV-1 infection has yielded positive results after 96 weeks of treatment.
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), today announced top-line results from its Phase 3 ENHANCE study, which evaluated pimavanserin as an adjunctive treatment in adult schizophrenia patients with persistent inadequate response to their current antipsychotic therapy.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.